Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?
Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.
Pharma & Biotech
Pharma & Biotech
How Priovant’s brepocitinib advances a long-overlooked inflammatory skin disease toward approval
Strong Phase 2 data put brepocitinib on a rare pivotal path in cutaneous sarcoidosis. Find out what this changes for clinicians and regulators.
Pharma & Biotech
Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.